| Cat. No. | Product name | CAS No. |
| DC66862 |
Itepekimab
Featured
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). |
2226742-52-3 |
| DC66863 |
Tozorakimab
Featured
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease. |
2376858-66-9 |
| DC66864 | Torudokimab Featured | |
| DC66865 |
Etokimab
Featured
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis. |
2022981-44-6 |
| DC66866 |
Talacotuzumab
Featured
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. |
1826831-79-1 |
| DC66867 | SNG-CD123A Featured | |
| DC66868 | MEDI2045 Featured | |
| DC66869 |
Depemokimab
Featured
Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma. |
2243274-14-6 |
| DC66870 | Abgenix anti-IL-5 Featured | |
| DC66871 | 1-Propanone, 1-(3-chlorophenyl)-3-(methylthio)- Featured | 1341108-31-3 |
| DC66872 | 4-Hepten-3-one, 1,7-bis(4-hydroxy-3-methoxyphenyl)- Featured | 79067-88-2 |
| DC66873 | 4-Hepten-3-one, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (4Z)- Featured | 81569-02-0 |
| DC66874 | WAY-311207-A Featured | 58575-74-9 |
| DC66875 |
CDK1-IN-2
Featured
CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM). |
220749-41-7 |
| DC66876 | Rpn11-IN-1 Featured | 2084857-65-0 |
| DC66877 |
New Red
Featured
New Red is a color additive that can be used to dye flour as well as meat products. |
220658-76-4 |
| DC66878 | 9-(dimethylamino)-3-(4-ethylphenyl)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one Featured | 869802-44-8 |
| DC66879 | ST-14328 Featured | |
| DC66880 | 8-Quinolinecarboxamide, 1,2-dihydro-2,2,4-trimethyl-N-[(1S,2E)-3-(methylsulfonyl)-1-(phenylmethyl)-2-propen-1-yl]- Featured | 2741881-50-3 |
| DC66881 |
WNK1-IN-1
Featured
WNK1-IN-1 is a selective inhibitor of WNK1 with an IC50 value of 1.6 μM. WNK1-IN-1 inhibits OSR1 phosphorylation with an IC50 value of 4.3 μM. WNK1-IN-1 can be used for the research of blood pressure regulation and cancer. |
324022-39-1 |
| DC66882 |
sRANKL inhibitor S3-15
Featured
sRANKL inhibitor S3-15 is a highly potent, orally active inhibitor of soluble RANKL, selectively interrupt soluble RANKL-RANK interaction and without interfering with the membrane RANKL-RANK interaction, shows potent osteoclast inhibition effect with IC50 of 0.19 uM in vitro. |
2412947-15-8 |
| DC66883 | Halosulfuron Featured | 135397-30-7 |
